Institutional & Family Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Institutional & Family Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-128	Closed	-$1K	–	945
2019 Q4	$1K	Hold	128	–	–	﹤0.01%	847
2019 Q3	$1K	Sell	128 -4	-3%	-$20	﹤0.01%	826
2019 Q2	$1K	Hold	132	–	–	﹤0.01%	837
2019 Q1	$1K	Hold	132	–	–	﹤0.01%	833
2018 Q4	$1K	Hold	132	–	–	﹤0.01%	813
2018 Q3	$1K	Hold	132	–	–	﹤0.01%	836
2018 Q2	$1K	Hold	132	–	–	﹤0.01%	833
2018 Q1	$1K	Buy	+132	New	+$878	﹤0.01%	831

Other funds holding PGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Institutional & Family Asset Management's PGNX Position: Q1 2020 in Review

Institutional & Family Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 128 shares — an estimated $1K sold.

Institutional & Family Asset Management first reported a position in PGNX in Q1 2018 and held it in 8 quarters. The position peaked at $1K in Q4 2019. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

Institutional & Family Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
Institutional & Family Asset Management sold 128 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $1K.
Institutional & Family Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2018 and held it in 8 quarters.
Institutional & Family Asset Management's Progenics Pharmaceuticals Inc position peaked at $1K in Q4 2019.
129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on Institutional & Family Asset Management's 13F filing for Q1 2020, filed 14 May 2020.